-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Bio-Techne Corporation published a major article in the World Journal of Urology on February 14 entitled "Pre-diagnostic Urinary Exosomal RNA (ExoDx EPI Score)" correlated with pathological outcomes after prostatectomy
According to the American Cancer Society, active surveillance is often used to closely monitor prostate cancer
The study included 2066 subjects and explored the applicability of exosome-based non-invasive urine testing in actively monitored low-risk male patients
The EPI test was validated in patients with initial biopsies and in men with negative previous biopsies
Prostate cancer (PCa) is the leading cause of cancer death in men in the United States, with more than 3.
Dr Alexander Kretschmer, a urologist from Ludwig Maximilian University in Munich, Germany, said: "From a clinical point of view, active surveillance (AS) is underutilized in patients with low-risk localized prostate cancer and more tools are needed to inform AS This study showed that the
"This study has important implications for the 75% of men who would be eligible for active surveillance programs and potentially avoid radical prostatectomy," said Chuck Kummeth, president and CEO of Bio-Techne
About Bio-Techne Corporation (NASDAQ: TECH) Contact: David Clair, Senior Director, Investor Relations and Corporate Development david.
Source Bio-Techne
